Biodesix, Inc. operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of mal⦠read more
Healthcare
Diagnostics & Research
2 years
USD
Exclusive to Premium users
$0.40
Price-0.18%
$0.00
$58.111m
Small
-
Premium
Premium
-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow Margin$74.463m
-
1y CAGR-
3y CAGR-
5y CAGR-$40.418m
-
1y CAGR-
3y CAGR-
5y CAGR-$0.30
-
1y CAGR-
3y CAGR-
5y CAGR$11.060m
$86.241m
Assets$75.181m
Liabilities$62.285m
Debt72.2%
-2.3x
Debt to EBITDA-$45.263m
-
1y CAGR-
3y CAGR-
5y CAGR